Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025
Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is back in the spotlight today after releasing positive top-line results from the first cohort of its FDA‑approved Phase I/IIa clinical trial for CMND‑100 in alcohol use disorder (AUD). The update lands just one day after the company highlighted a new Israeli patent filing for a non‑hallucinogenic depression therapy, and as a fresh equity offering is expected to close around today’s date. GlobeNewswire+2GlobeNewswire+2 The cluster of announcements is drawing intense trading interest. As of mid‑afternoon on November 18, CMND shares were changing hands around $0.27, after touching an intraday high near $0.39, on